v3.26.1
Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited) - USD ($)
Preferred shares
Ordinary shares
Additional paid-in Capital
Accumulated Deficit
Accumulated Other comprehensive loss
Total
Balance at Dec. 31, 2024   $ 23,054 $ 95,215,079 $ (88,691,657) $ (548,631) $ 5,997,845
Balance (in Shares) at Dec. 31, 2024   2,319,353        
Stock option expense   856,286 856,286
Share issuance for exercise of pre- funded warrants   $ 6,982 $ (6,317) 665
Share issuance for exercise of pre- funded warrants (in Shares)   665,000        
Sale of ordinary shares    
Sale of ordinary shares (in Shares)        
Share-based expense   $ 566 $ 362,964 363,530
Share-based expense (in Shares)   54,500        
Net loss   (5,002,891) (5,002,891)
Foreign currency translation   163,849 163,849
Balance at Mar. 31, 2025   $ 30,602 96,428,012 (93,694,548) (384,782) 2,379,284
Balance (in Shares) at Mar. 31, 2025   3,038,853        
Balance at Dec. 31, 2024   $ 23,054 95,215,079 (88,691,657) (548,631) 5,997,845
Balance (in Shares) at Dec. 31, 2024   2,319,353        
Stock payable for acquisition of intellectual property          
Reclassification of translation adjustment related to liquidation of foreign subsidiary          
Net loss           (8,482,724)
Balance at Jun. 30, 2025   $ 41,572 100,268,071 (97,174,381) (524,908) 2,610,354
Balance (in Shares) at Jun. 30, 2025   4,091,853        
Balance at Mar. 31, 2025   $ 30,602 96,428,012 (93,694,548) (384,782) 2,379,284
Balance (in Shares) at Mar. 31, 2025   3,038,853        
Stock option expense   160,187 160,187
Share issuance for exercise of pre- funded warrants   $ 6,805 (6,202) 603
Share issuance for exercise of pre- funded warrants (in Shares)   603,000        
Sale of ordinary shares and warrants and prefunded warrants   $ 3,309 3,530,180 3,533,489
Sale of ordinary shares and warrants and prefunded warrants (in Shares)   375,000        
Share-based expense   $ 856 155,894 156,750
Share-based expense (in Shares)   75,000        
Reclassification of translation adjustment related to liquidation of foreign subsidiary          
Net loss   (3,479,833) (3,479,833)
Foreign currency translation   (140,126) (140,126)
Balance at Jun. 30, 2025   $ 41,572 100,268,071 (97,174,381) (524,908) 2,610,354
Balance (in Shares) at Jun. 30, 2025   4,091,853        
Balance at Dec. 31, 2025 $ 107,820 106,053,809 (104,902,375) (617,654) 641,600
Balance (in Shares) at Dec. 31, 2025 9,780,142        
Stock option expense 176,531 176,531
Sale of preferred shares $ 35,604 2,964,396 3,000,000
Sale of preferred shares (in Shares) 3,000,000        
Sale of ordinary shares $ 20,314 2,067,925 2,088,239
Sale of ordinary shares (in Shares) 1,735,194        
Share-based expense $ 11,868 788,132 800,000
Share-based expense (in Shares)   1,000,000        
Preferred shares payable 3,000,000 3,000,000
Net loss (5,081,982) (5,081,982)
Foreign currency translation (35,096) (35,096)
Balance at Mar. 31, 2026 $ 35,604 $ 140,002 115,050,793 (109,984,357) (652,750) 4,589,292
Balance (in Shares) at Mar. 31, 2026 3,000,000 12,515,336        
Balance at Dec. 31, 2025 $ 107,820 106,053,809 (104,902,375) (617,654) $ 641,600
Balance (in Shares) at Dec. 31, 2025 9,780,142        
Ordinary shares issued for in-process research and development (in Shares)           2,121,386
Stock payable for acquisition of intellectual property           $ 5,470,400
Reclassification of translation adjustment related to liquidation of foreign subsidiary           683,433
Net loss           (16,098,462)
Balance at Jun. 30, 2026 $ 59,092 $ 286,063 141,019,021 (121,000,837) 20,363,339
Balance (in Shares) at Jun. 30, 2026 5,000,000 24,929,290        
Balance at Mar. 31, 2026 $ 35,604 $ 140,002 115,050,793 (109,984,357) (652,750) 4,589,292
Balance (in Shares) at Mar. 31, 2026 3,000,000 12,515,336        
Preferred shares issued $ 23,488 (23,488)
Preferred shares issued (in Shares) 2,000,000        
Ordinary shares issued for exercise of warrants $ 102,669 15,132,372 15,235,041
Ordinary shares issued for exercise of warrants (in Shares) 8,700,854        
Ordinary shares issued for in-process research and development $ 24,617 3,233,832 3,258,449
Ordinary shares issued for in-process research and development (in Shares) 2,121,386        
Stock option expense (528,922) (528,922)
Stock payable for acquisition of intellectual property 5,470,400 5,470,400
Share-based expense payable 2,263,250 2,263,250
Share-based expense   $ 18,775 420,784 439,559
Share-based expense (in Shares)   1,591,714        
Reclassification of translation adjustment related to liquidation of foreign subsidiary 683,433 683,433
Net loss (11,016,480) (11,016,480)
Foreign currency translation (30,683) (30,683)
Balance at Jun. 30, 2026 $ 59,092 $ 286,063 $ 141,019,021 $ (121,000,837) $ 20,363,339
Balance (in Shares) at Jun. 30, 2026 5,000,000 24,929,290